Skip to main content
. 2024 Dec 13;19(1):66–69. doi: 10.1097/ICB.0000000000001516

Fig. 2.

Fig. 2.

Progression of RHB on MRI. A. MRI before initiation of belzutifan that showed tumor size of 2.0 cm × 1.2 cm. Outer red diameter lines represent transscleral component. B. MRI after 4 months of belzutifan therapy that showed tumor regression to 1.4 cm × 0.8 cm. C. MRI after 1 year of belzutifan therapy with evidence of significant tumor regression to 1.1 cm × 0.5 cm.